These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37254175)

  • 21. Angiotensin II in septic shock.
    Jadhav AP; Sadaka FG
    Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.
    Wieruszewski PM; Wittwer ED; Kashani KB; Brown DR; Butler SO; Clark AM; Cooper CJ; Davison DL; Gajic O; Gunnerson KJ; Tendler R; Mara KC; Barreto EF
    Chest; 2021 Feb; 159(2):596-605. PubMed ID: 32882250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II: a new approach for refractory shock management?
    Kimmoun A; Levy B
    Crit Care; 2014 Dec; 18(6):694. PubMed ID: 25645552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating Vasopressor Discontinuation Strategies in Patients With Septic Shock on Concomitant Norepinephrine and Vasopressin Infusions.
    Musallam N; Altshuler D; Merchan C; Zakhary B; Aberle C; Papadopoulos J
    Ann Pharmacother; 2018 Aug; 52(8):733-739. PubMed ID: 29560736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopressors for hypotensive shock.
    Havel C; Arrich J; Losert H; Gamper G; Müllner M; Herkner H
    Cochrane Database Syst Rev; 2011 May; (5):CD003709. PubMed ID: 21563137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.
    Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S
    J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasopressors for shock.
    Müllner M; Urbanek B; Havel C; Losert H; Waechter F; Gamper G
    Cochrane Database Syst Rev; 2004; (3):CD003709. PubMed ID: 15266497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An updated "norepinephrine equivalent" score in intensive care as a marker of shock severity.
    Kotani Y; Di Gioia A; Landoni G; Belletti A; Khanna AK
    Crit Care; 2023 Jan; 27(1):29. PubMed ID: 36670410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasopressor Discontinuation Order in Septic Shock With Reduced Left Ventricular Function.
    Taylor A; Jones T; Forehand CC; Smith SE; Dykes H; Newsome AS
    J Pharm Pract; 2022 Dec; 35(6):879-885. PubMed ID: 33977793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of Vasopressin Use for Adults with Septic Shock.
    Vail EA; Gershengorn HB; Hua M; Walkey AJ; Wunsch H
    Ann Am Thorac Soc; 2016 Oct; 13(10):1760-1767. PubMed ID: 27404213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis.
    Busse LW; Nicholson G; Nordyke RJ; Lee CH; Zeng F; Albertson TE
    Int J Technol Assess Health Care; 2020 Apr; 36(2):145-151. PubMed ID: 32114996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is vasopressin an ideal vasopressor to treat hypotension in septic shock?
    Romand JA; Treggiari-Venzi M
    Intensive Care Med; 1999 Jul; 25(7):763-4. PubMed ID: 10577013
    [No Abstract]   [Full Text] [Related]  

  • 33. The Role of Angiotensin II in Poisoning-Induced Shock-a Review.
    Chen A; Wong A
    J Med Toxicol; 2022 Apr; 18(2):145-154. PubMed ID: 35258848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS).
    Jeon K; Song JU; Chung CR; Yang JH; Suh GY
    Crit Care; 2018 May; 22(1):131. PubMed ID: 29784057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasopressors to treat refractory septic shock.
    Meresse Z; Medam S; Mathieu C; Duclos G; Vincent JL; Leone M
    Minerva Anestesiol; 2020 May; 86(5):537-545. PubMed ID: 31994366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed vasopressor initiation is associated with increased mortality in patients with septic shock.
    Colon Hidalgo D; Patel J; Masic D; Park D; Rech MA
    J Crit Care; 2020 Feb; 55():145-148. PubMed ID: 31731173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catecholamine-Sparing Effect of Angiotensin II in an Anephric Patient With Mixed Shock After Cardiac Revascularization Surgery: A Case Report.
    Cutler NS; Khanna AK
    A A Pract; 2020 Jul; 14(9):e01266. PubMed ID: 32909718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Vasopressin as First-Line Treatment of Distributive and Hemorrhagic Shock States.
    Haan BJ; Cadiz ML; Natavio AM
    Ann Pharmacother; 2020 Mar; 54(3):213-218. PubMed ID: 31625395
    [No Abstract]   [Full Text] [Related]  

  • 39. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.
    McIntyre WF; Um KJ; Alhazzani W; Lengyel AP; Hajjar L; Gordon AC; Lamontagne F; Healey JS; Whitlock RP; Belley-Côté EP
    JAMA; 2018 May; 319(18):1889-1900. PubMed ID: 29801010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Refractory Vasodilatory Shock.
    Jentzer JC; Vallabhajosyula S; Khanna AK; Chawla LS; Busse LW; Kashani KB
    Chest; 2018 Aug; 154(2):416-426. PubMed ID: 29329694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.